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Abstract: CircRNAs are a class of noncoding RNA species with a circular configuration that is formed
by either typical spliceosome-mediated or lariat-type splicing. The expression of circRNAs is usually
abnormal in many cancers. Several circRNAs have been demonstrated to play important roles in
carcinogenesis. In this review, we will first provide an introduction of circRNAs biogenesis, especially
the regulation of circRNA by RNA-binding proteins, then we will focus on the recent findings of
circRNA molecular mechanisms and functions in cancer development. Finally, some open questions
are also discussed.
Keywords: circRNAs; carcinogenesis; biogenesis; RNA-binding protein; flanking introns; genomic
alternation
1. Introduction
Discovered more than three decades ago [1], circRNAs have attracted extensive attention in recent
years [2–4]. As a member of the noncoding RNA family, circRNAs display a unique covalently closed
circular form, which distinguishes it from its other noncoding RNA cousins such as microRNA and
lncRNA. High-throughput RNA-seq studies have detected a large number of circRNAs with different
lengths and types. Initial analyses of the sequencing data indicate they are specifically expressed during
tissue/developmental stages and conserved between mice and humans [3,4]. Emerging evidence has
demonstrated that some circRNAs have various biological functions and play potentially important
roles in multiple diseases such as cancers [5–7].
Here, we summarize the expanding findings on circRNA and provide an up-to-date account of
their biogenesis, regulatory mechanisms, and cellular functions in carcinogenesis.
2. The Biogenesis of circRNAs in Cancers
In eukaryotes, linear mRNA is formed by processing exons of pre-mRNAs through alternative
splicing. Unlike linear RNAs, circRNAs were originally thought to be aberrant RNA splicing
products [8]. Because of their covalent closed-loop structure, circRNAs are protected from degradation
by RNases, so they are more stable than linear RNAs [3]. When analyzing 17 different cancer cohorts
from the MiOncoCirc compendium, Vo et al. characterized circRNAs across >2000 cancer samples and
observed a general decrease in total circRNA abundance compared to the adjacent normal tissues [9].
With the optimization of next-generation sequencing technology, several circRNA subtypes
have been discovered in recent years. There are four main subtypes of circRNAs: exonic circRNAs
(ecircRNAs), which are mainly derived from single or several exons; on the other side, circular intronic
Int. J. Mol. Sci. 2019, 20, 3926; doi:10.3390/ijms20163926 www.mdpi.com/journal/ijms
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RNAs (ciRNAs) contain only introns; exonic-intronic circRNAs (EIciRNAs), which consist of both
introns and exons; and tRNA intronic circRNAs (tricRNAs) are formed by splicing pre-tRNA intron
(Figure 1). Currently, most of the identified circRNAs are exonic circRNAs.
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Figure 1. Biogenesis of circRNAs. (A) Lariat-driven circularization. When a pre-mRNA is spliced, the
3′ hydroxyl of the upstream exon interacts with the 5′ phosphate of the downstream exon to form a
covalent linkage, producing a lariat that contains exons and introns. The 2′ hydroxyl of the 5′ intron
reacts with the 5′ phosphate of the 3′-intron, foll wed by an interaction between the 3′ hydroxyl of the
3′ exon and the 5′ phosphate of the 5′ exon, through which an ecircRNA is formed. (B) RNA-binding
protein (RBP)-driven circularization. RBPs can promote the interaction of the downstream intron and
upstream intron, causing the formation of an ecircRNA. (C) Base-pairing-driven circularization. The
downstream introns and upstream introns are paired based on inverse-repeating or complementary
sequences. The introns are removed or retained to form ecircRNA or EIciRNA. (D) Biosynthesis of
ciRNA. Formation of ciRNAs mainly depends on a 7-nt GU-rich element and an 11-nt C-rich element
to escape debranching and exonucleolytic degradation. (E) Formation of tricRNA. tRNA splicing
enzymes divide pre-tRNA into two parts: tricRNAs are generated by a 3′–5′ phosphodiester bond, and
the other part generates tRNAs.
The formation mechanisms of different types of circRNAs are also diversely regulated. Generation
of exonic circRNAs can be achieved by both lariat-driven circularization and back splicing. When
the upstream splice acceptor and downstream donor are close to forming a lariat containing the
exons, the introns in the lariat are removed, and the exons are joined by a 5′–3′ phosphodiester
bond (Figure 1A) [10]. Interactions between RNA-binding proteins (RBPs) form a ‘bridge’ within the
upstream and downstream introns, followed by back splicing to form ecircRNAs (Figure 1B) [11,12].
During base-pairing-driven circularization, the downstream splicing donor is connected to the upstream
splicing receptor depending on ALU complementary sequences. In the process of circRNA formation,
the introns are removed or retained to form ecircRNA or EIciRNA(Figure 1C) [3]. The biosynthesis of
ciRNAs mainly depends on a 7-nt GU-rich element and an 11-nt C-rich element to escape debranching
and exonucleolytic degradation (Figure 1D) [13]. Unlike ecircRNAs, which are mainly located in the
cytoplasm, ciRNAs and EIciRNAs are mainly distributed in the nucleus and play a crucial role in
regulating parental gene transcription. A special intronic circRNA, tricRNA, has been found in Archaea
and Drosophila [14–16]. The formation of tricRNA needs tRNA splicing enzymes to divide pre-tRNA
into two parts: tricRNAs are generated by a 3′–5′ phosphodiester bond, and the other part generates
tRNAs (Figure 1E) [15]. It is generally accepted that both the binding of RNA proteins and the presence
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of specific and repetitive sequences in the introns surrounding the circularizing exons determine the
production of circRNAs.
2.1. Introns Flank circRNAs
Previously, analysis of the surrounding introns of circRNAs in human fibroblasts has indicated
they are usually longer and harbor complementary ALU repeats [3]. A recent analysis of circRNAs in
over 2000 cancer samples confirmed this finding [9]. These repetitive sequences are thought to facilitate
circular RNA formation [17]. Besides, Ivanov et al. found that the reverse complementary sequences
are conserved and highly enriched within introns that bracket circRNAs. They also successfully
developed a computational system to identify novel circRNAs based on scoring the presence of reverse
complementary sequences in human introns [18]. Furthermore, introns upstream or downstream
circularized exons, are preferentially harbor more RNA editing events, which proved to affect the
formation of circRNA [18,19].
2.2. Regulation of circRNA Biogenesis by RNA-Binding Proteins (RBPs)
RNA-binding proteins, which usually contain RNA-binding motifs, play a central role in
transcriptional regulation of genes [20]. Because of the development of high-throughput methods,
such as RNA sequencing and mass spectrometry, about ~1500 RBPs have been identified from
the human genome until now [21,22]. Bioinformatics analyses of the alteration spectrum across
thousands of human cancers samples identified ~9% of cancer-related RBPs, highlighting its potential
roles in tumorigenesis [23]. RBPs can shorten the distance between the donor site and the receptor
site by binding to the introns on the flank regions, thus promoting circularization of the exons in
circRNA biogenesis.
QKI, KH domains containing RNA binding proteins, is the first identified RBP involved in circRNA
formation during the epithelial to mesenchymal transition. It enhances circRNA formation by binding
to its consensus target motif, single-stranded RNA (ssRNA), in introns that flank the circRNA-forming
exons. Consequently, insertion of synthetic QKI binding sites into introns was sufficient to produce
circRNAs [12]. Based on genome-wide siRNA screening and circRNA expression reporter assays, Li
et al. identified that the immune factors nuclear factor 90 and its 110 isoform (NF90/NF110) could
couple circRNA biogenesis and function during viral infection. They found the nuclear export of
NF90/NF110 to the cytoplasm correlated with decreased circRNA expression, while NF90/NF110 bound
to viral mRNAs to stimulate an antiviral immune response [24]. Epithelial splicing regulatory protein
1 (ESRP1) is an essential splicing factor during pluripotency [25]. A recent report found an elegant
regulating network involved in circRNA and RNA-binding protein in human embryonic stem cells
(hESCs). In this scenario, NANOG and OCT4 regulate ESRP1 expression in hESCs, which leads to
the promotion of circBIRC6 generation. Consequently, circBIRC6 works as a ‘molecular reservoir’ of
miR-34a and miR-145, collectively contributing to pluripotency maintenance [26].
Different RBPs may play different, or even opposite, roles in the back-splicing process. For example,
all the above three RBPs can promote the production of circRNAs, whereas the RNA-editing enzyme
(that edits adenosine to inosine) acts on RNA enzyme 1 (ADAR1) to inhibit circRNA formation [18].
ADAR1 binds double-stranded RNA to mediate adenosine-to-inosine (A-to-I) RNA editing [27]. Large
scale analyses of multiple cancer samples from The Cancer Genome Atlas (TCGA) indicate RNA editing
events in tumor samples correlate best with the ADAR1 expression level globally. Approximately
3.5% of detected RNA editing sites are associated with potential clinical relevance, many of which are
in noncoding regions [19]. This is consistent with a report that A-to-I editing is also enriched with
the base-paired or proximal regions of circularized exons [18]. A mechanistic model suggested RNA
editing sites may disrupt the RNA–RNA interactions of introns to form larger structures [28]. This is
supported by the evidence that ADAR1 depletion can up-regulate the formation of circRNAs [18]. The
known instances of RBPs have been summarized in Table 1.
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Table 1. RNA-binding proteins that regulate circRNA biogenesis.
Gene Effect on the Formation of circRNA Mechanisms PMID
QKI Promote QKI enhances circRNA formation by binding to its consensus target single-stranded RNA (ssRNA) motif in intronsthat flank circRNA-forming exons. 25768908
TNRC6A Promote The RNA-binding protein TNRC6A binds to the flanking intron sequence of circHOMER1 and regulates theformation of circHOMER1. In the absence of TNRC6A, circHOMER1 cannot be effectively looped. 29726904
NF90/NF110 Promote NF90/NF110 stimulates circRNA formation by promoting the stability of intron complementary sequences 28625552
HNRNPL Promote Circular RNA formation regulated by HNRNPL back splicing. 28611215
MBL/MBNL1 Promote MBL/MBNL1 strongly and specifically binds with circMbl flanking introns, which contain conserved muscleblindbinding sites and strongly affects circMbl biosynthesis 25242144
ESRP1 Promote The splicing factor ESRP1, which is controlled by the core pluripotency-associated factors, OCT4 and NANOG, canlead to the promotion of circBIRC6 generation. 29074849
FUS Inhibit FUS was found to regulate circRNA generation by binding introns that flank back-splicing junctions 28358055
DHX9 Inhibit DHX9 can bind to IRAlus and possesses RNA helicase activity. It wasspeculated that DHX9 may inhibit circRNA expression by unwinding RNA pairs that flank circularized exons. 28355180
ADAR1 Inhibit ADAR1 binds double-stranded RNA to mediate adenosine-to-inosine (A-to-I) RNA editing to inhibitcircRNA formation. 25558066
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2.3. Impacts of Genomic Alterations on the Formation of circRNAs
Oncogenic gene fusion is commonly found in cancer samples and plays a role in carcinogenesis.
Guarnerio et al. hypothesized chromosome rearrangement will result in the juxtaposition at a close
enough proximity to favor new events of back splicing, which would promote the generation of
aberrant circRNAs [29]. To verify this hypothesis, they examined the most recurrent translocation
fusion genes, such as PML-RARa and MLL/AF9 fusion genes, in leukemia. Circular forms of fusion
circRNAs (f-circRNA) are indeed produced from transcribed exons of distinct genes and affected by
the translocations. Furthermore, they also found circular EWSR1/FLI1 fusion in SK-NEP-1 sarcoma
cells and EML4/ALK1 in H3122 lung cancer cells. However, a recent search of MiOncoCirc data, which
included 17 cancer sequencing datasets, did not detect any f-circRNAs resulting from chromosomal
translocations and deletions. Instead, they discovered read-through circRNA (rt-circRNA), a novel
class of circular transcripts that span exons originating from two adjacent genes on the same strand.
They found some of these rt-circRNA reads were commonly found across different cancer types, and
they were even detected in normal tissues or in samples with a normal copy number of the parent
genes, which indicated the prevalence of rt-circRNAs in cancer samples [9].
3. Functional Mechanisms of circRNAs
The functional mechanism of circRNAs are diverse in human cancer including acting as miRNA
sponges, interacting with protein, regulating gene splicing or transcription, translating proteins, or
peptide and epigenetic regulation (Figure 2). According to the targets of circRNAs, they can generally
be classified into two categories: one is to regulate its hosting gene, the other is to target different ones.
We have summarized the known instances in Table 2.
3.1. Interfering with Parental Gene Regulation
Accumulated reports observed that circRNA can, in a complicated way, regulate its parental
gene in terms of epigenetic control, splicing, transcription, or translation. For example, Chen et al.
reported that circFECR1, a FLI1 exonic circular RNA, interacts with the FLI1 promoter and recruits
TET1 demethylase to induce DNA demethylation in the CpG islands. Concurrently, circFECR1 also
binds to and downregulates DNMT1, the critical enzyme that maintains DNA demethylation during
DNA replication. Thus, circFECR1 promotes tumor cell invasion by coordinately regulating TET1 and
DNMT1 in breast cancers [30].
If the circRNA contains the same exon as the parental gene, the processing of circRNA will
compete with the splicing of pre-mRNA. Previous studies have shown that back-splicing can compete
with pre-mRNA splicing in circRNA biogenesis, resulting in low levels of linear mRNA that contain
exon inclusions. In general, the more an exon is circularized, the less it presents in the processed
mRNA [8,11].
CircRNA can also affect the transcription of its parental gene. For example, intron-retained
circRNAs, such as EIciRNA are located in the nucleus. It is reported that EIciRNAs can bind to
U1 snRNPs through RNA–RNA interactions, while U1 forms a complex with RNA polymerase II
by binding to TFIIH. EIciRNAs regulate RNA polymerase II activity and promote parental gene
transcription [28]. Similar to EIciRNA, ciRNA also can stimulate the transcription of its parental gene
by up-regulating the activity of RNA polymerase II and enhance the expression of ankyrin repeat
domain 52 protein (ANKRD52) [13].
Besides, some circRNAs have been demonstrated to regulate gene transcription via both RNA
polymerase II complex and translation-related proteins. Recently, circYap was found to bind with Yap
mRNA and the translation initiation associated proteins eIF4G and PABP. The complex containing
overexpressed circYap abolishes the interaction of PABP on the poly (A) tail and eIF4G on the 5′-cap of
the Yap mRNA, which functionally leads to the suppression of Yap translation initiation. Individually
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blocking the binding sites of circYap on Yap mRNA, or respectively mutating the binding sites for PABP
and eIF4G, de-represses Yap translation [31].Int. J. Mol. Sci. 2019, 20, x  12 of 18 
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ciRNAs and EIciRNAs, with retained introns, can bind to U1 snRNP through RNA–RNA interactions
and further interact with the Pol II transcription co plex to enhance parental gene expression. (C)
Circular R FECR1 fro FLI1 gene interacts ith FLI1 pro oter, recruits TET1 de ethylase, and
induces extensive DNA demethylation in the CpG islands. In addition, FECR1 inhibitsDNMT1, a critical
enzyme that aintains DNA demethylation during DNA replication, by binding to its promoter region
rich in H3K27ac. (D) miRNA sponges. CircRNA affects the expression of miRNA and downstream
target genes by adsorbing miRNAs. (E) Protein sponges. CircRNA regulates target proteins by binding
to them. (F) Translati n. CircRNAs can be translated into peptides or proteins.
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Table 2. Different mechanism of circRNAs in human cancers.
Function CircRNA Cancer Type Expression Targeting miRNA orGenes Mechanisms PMID
Acting as miRNA
sponge
circAGFG1 TNBC Up miR-195-5p/CCNE1
CircAGFG1 can promote TNBC cell proliferation, mobility, and invasion as
well as tumorigenesis and metastasis in vivo by acting as a ceRNA
(competing endogenous RNA) of miR-195-5p to relieve the repressive effect of
miR-195-5p on its target cyclin E1 (CCNE1).
30621700
circHIPK3 CRC Up miR-7/FAK, IGF1R,YY1, EGFR circHIPK3 promotes proliferation/migration 29549306
circCDR1 ESCC Up miR-7/HOXB13 CirsCDR1 functions as the sponge of miR-7 and reactivates its downstreamHOXB13-mediated NF-κB/p65 pathway. 30082829
circHIPK3 BCa Down miR-558/HPSE
circHIPK3 targets miR-558 to suppress the expression of HPSE and inhibits
migration, invasion, and angiogenesis of bladder cancer cells in vitro and
suppresses bladder cancer growth and metastasis in vivo.
28794202
circTRIM33-12 HCC Down miR-191/ TET1 CircTRIM33-12 upregulate TET1 expression by sponging miR-191, resulting insignificantly reduced 5-hydroxymethylcytosine (5hmC) levels in HCC cells. 31153371
circTADA2As TNBC Down miR-203a-3p/SOCS3 circTADA2As suppresses cell proliferation, migration, invasion, andclonogenicity and possesses a tumor-suppressor capability. 30787278
circLARP4 GC Down miR-424-5p/ LATS1 circLARP4 is mainly localized in the cytoplasm and inhibits biologicalbehaviors of GC cells by sponging miR-424. 28893265
circATP2B1 ccRCC Down miR-204-3p/FN1 CircATP2B1 is suppressed by ERβ, and then reduces miR-204-3p, whichincreases fibronectin 1 expression and enhances ccRCC cell invasion. 29490945
circITCH BCa Down miR-17, miR-224/p21,PTEN
circITCH promotes the aggressive biological behaviors of BCa via
up-regulating the expression of p21 and PTEN through ‘sponging’ miR-17
and miR-224
29386015
circMTO1 HCC Down miR-9/ p21 circMTO1 can down-regulate p21 by acting as the sponge of oncogenic miR-9to suppress hepatocellular carcinoma progression. 28520103
circDB HCC Up miR-34a/USP7 CircDB promotes tumor growth and reduces DNA damage by suppressingmiR-34a and activating the USP7/Cyclin A2 signaling pathway 30546088
Binding to proteins
CircACC1 CRC Up AMPK
CircACC1 functions to stabilize and promote the enzymatic activity of the
AMPK holoenzyme by forming a ternary complex with the regulatory β and
γ subunits.
31155494
circDNMT1 BRCA Up P53, AUF1
Ectopically expressed circDnmt1 promotes the nuclear translocation of both
p53 and AUF1, p53 nuclear translocation induces cellular autophagy, while
AUF1 nuclear translocation reduces Dnmt1 mRNA instability, resulting in
increased Dnmt1 translation.
29973691
circAGO2 GC Up HuR
circAGO2 binds with HuR protein to promote its activation and enrichment on
the 3′-untranslated region of target genes, which reduces AGO2 binding and
repression of AGO2/miRNA-mediated gene silencing
30341421
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Table 2. Cont.
Function CircRNA Cancer Type Expression Targeting miRNA orGenes Mechanisms PMID
Binding to proteins
circPABPN1 Hela cell Up HuR The binding of CircPABPN1 to HuR inhibits HuR binding to PABPN1 mRNAand reduces PABPN1 translation. 28080204
circFOXO3 BRCA Down circFOXO3, p53 CircFoxo3 promotes MDM2-induced p53 ubiquitination and subsequentdegradation by binding to Foxo3 protein and p53, resulting in cell apoptosis. 27886165
circCCNB1 BRCA Down Ccnb1/Cdk1 CircCcnb1 can interact with both Ccnb1 and Cdk1 proteins. Ectopic delivery ofcircCcnb1 inhibits tumor growth and extends mouse viability. 31199987
Translating proteins
or peptide
circCTNNB1 HCC Up 370-amino acid
β-catenin isoform
CircCTNNB1 produces a novel, 370 amino acid β-catenin isoform that uses the
start codon as the linear β-catenin mRNA transcript, and translation is
terminated at a new stop codon created by circularization.
31027518




in CESC and HNSC
Up E7 protein
Specific disruption of circE7 in CaSki cervical carcinoma cells reduces E7
protein levels and inhibits cancer cell growth both in vitro and in
tumor xenografts.
31127091
circSHPRH GBM Down SHPRH-146aa SHPRH-146aa is a tumor suppressor in human glioblastoma, which istranslated by circ-SHPRH. 29343848
circFBXW7 GBM Down FBXW7-185aa
The spanning junction open reading frame in circ-FBXW7 driven by internal
ribosome entry site encodes a novel 21 kDa protein (FBXW7-185aa).






circFECR1 BRCA Up TET1, DNMT1. CircFECR1 regulates DNA methylation and demethylation enzymes tocontrol breast cancer tumor growth. 30537986
circYAP BRCA Up eIF4G, PABP
CircYap can bind with Yap mRNA and the translation initiation associated
proteins, eIF4G and PABP, which functionally leads to the suppression of Yap
translation initiation.
31092884
circEIF3J, circPAIP2 Hela, HEK293 Up U1 snRNA EIciRNAs predominantly localizes in the nucleus, interacts with U1 snRNP,and promotes transcription of their parental genes. 25664725
BRCA: breast cancer; GC: Gastric cancer; BCa: bladder cancer; CRC: colorectal cancer; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; HNSC: head and
neck squamous cell carcinoma; GBM: primary glioblastomas; HCC: hepatocellular carcinoma; TNBC: Triple-negative breast cancer; ccRCC: Clear Cell Renal Cell Carcinoma; and ESCC:
esophageal squamous cell carcinoma.
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3.2. Acting as miRNA Sponges
CircRNAs are stable in cells because they do not have a 5′end and a poly-A tail, which prevent
ribonuclease degradation. Furthermore, there are multiple miRNA response elements on the circular
sequences. Thus, circRNA is natural miRNA sponge. CDR1as consists of a single exon and 63
conserved binding sites for miR-7, can suppress miR-7’s activity, and can upregulate the expression of
miR-7 targets such as SNCA, EGFR, and IRS2 [2]. CircRNAs can inhibit the expression of miRNAs by
adsorption and, meanwhile, affect the molecular level of downstream target genes. Many studies have
shown that the most general function of circRNAs is its action as a miRNA sponge to regulate target
gene expression by inhibiting miRNA activity. One circRNA can regulate one or multiple miRNAs
through multiple miRNA binding sites. CircRNAs regulate gene expression through binding to and
releasing miRNAs from their downstream target genes. For example, we found circTADA2A was
repressed in a large cohort of triple-negative breast cancer (TNBC) patients compared to adjacent normal
tissues. Through bioinformatics analyses, miR-203a-3p and miR-302c-3p binding sites were identified
in circTADA2A, which was confirmed in subsequent wet experiments. Functional analysis indicated
circTADA2A-E6 binds with miR-203a-3p, thus affecting its downstream gene SOCS3 to suppress cell
migration, invasion, and clonogenicity. Furthermore, their down-regulation was correlated with
survival time in TNBC patients. We conclude that circTADA2A-E6 is a tumor-suppressor circRNA
and could be utilized as a promising prognostic biomarkers and therapeutic target for TNBCs [32].
Interestingly, an oncogenic circRNA in TNBC was also discovered in a recent report. Yang et al. found
that circAGFG1 was significantly up-regulated in TNBC, and it promoted TNBC progression through
the circAGFG1/miR-195-5p/CCNE1 axis [33]. The same circRNA may even target different miRNAs
to exert opposite functions in different cancers. For example, circHIPK3 targets miR-7 to promote
colorectal cancer growth and metastasis, while it also targets miR-558 to suppress the expression of
HPSE and inhibits migration, invasion, and angiogenesis of bladder cancer cells in vitro [34,35].
3.3. Binding to Proteins
Some circRNAs that harbor binding sites for RNA-binding proteins may serve as protein sponges
or decoys in addition to acting as miRNA sponges. For instance, the circular RNA Ccnb1 could bind
with H2AX in p53 mutant cells and suppress mutant p53 in tumor progression. This study found
that circ-Ccnb1 could interact with both Ccnb1 and Cdk1 proteins, thus counteracting the effects of p53
mutations in breast cancer [36]. In colorectal cancer tissues, increasing AMPK activation is usually
associated with upregulated expression of circACC1 [37]. CircACC1 functions to stabilize and promote
the enzymatic activity of the AMPK holoenzyme by binding with the regulatory β and γ subunits.
Argonaute 2 (AGO2) is a core component of the miRNA-induced silencing complex. Recently, Chen et
al. identified that circAGO2, one intronic circRNA generated from the AGO2 gene, binds with the
HuR protein to facilitate HuR-repressed functions of AGO2–miRNA complexes in gastric cancer [38].
CircRNA can also form functional complexes with proteins. CircFOXO3, which is highly expressed
in noncancer cells, could arrest the function of CDK2 and block cell cycle progression via formation
of a circFOXO3–p21–CDK2 ternary complex [39]. Undoubtedly, to coordinate the different cellular
processes, some of the proteins that bind with circRNA may also be an essential regulator of the
biogenesis of circRNA [24].
3.4. Translating Proteins or Peptide
circRNAs were initially defined as a distinct class of endogenous noncoding RNA that could not
translate proteins. Recently, strong evidence from several research groups has shown that circRNAs
can encode proteins. Liang et al. reported that circCTNNB1 produces a novel, 370 amino acid CTNNB1
(i.e., β-catenin) isoform that uses the start codon as the linear β-catenin mRNA transcript, and translation
is terminated at a new stop codon created by circularization. They found that this novel isoform
can stabilize full-length β-catenin by antagonizing GSK3β-induced β-catenin phosphorylation and
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degradation, leading to activation of the Wnt pathway [40]. In addition, Zhang et al. reported that
circular lncRNA-PINT can be translated into a small peptide to suppress glioblastoma cell proliferation;
this action is mediated by trapping PAF1c to inhibit translational elongation of oncogenes [41]. However,
the molecular mechanism of translation remains largely unknown. Generally speaking, linear mRNA
translation normally requires a 5′end 7-methylguanosine (m7G) cap structure and a 3′ poly-A tail.
CircRNA may be translated into peptides and proteins in other novel ways because circRNAs lack
both caps and poly(A) tails. One report indicated that circRNAs can be translated from an artificial
internal ribosomal entry site (IRES) to generate a functional green fluorescent protein (GFP) [42]. And
another mechanism is that circular RNA containing an infinite open reading frame (ORF) can be
efficiently translated to produce proteins [43]. Based on ribosome footprinting assays of fly head
extracts, Pamudurti et al. identified that a group of circRNAs is translated in a cap-independent
manner. They share the start codon with the hosting RNA, encoding specific domains from hosting
protein [44].
4. Perspectives
In recent years, considerable interest has focused on circRNA in cancers. In this review, we outline
current understandings on its biogenesis, molecular mechanism, and function, but there are also some
open questions. Firstly, controls of circRNA and its parental gene are thought to be intensely coupled
together [11,30,31]. However, Smid et al. developed a new circRNA prediction method, which did not
rely on unmapped reads or known splice junctions. When analyzing random-primed cDNA libraries
from a large primary breast cancer cohort, they found only a small part of circRNAs could be explained
by known splicing events [45]. Although it cannot completely rule out the technical disparities between
this study and previous investigations, it raises the possibility that specific regulatory processes and
functions for circRNAs exist. Future studies are needed to systematically compare the datasets and
analysis methods to clarify the relationship between circRNA and its host gene.
Besides, genetic or epigenetic factors contributing to circRNA regulation have not been fully
explored in cancers. For example, genomic aberrations include both chromosome translocation and
short nucleotide variants [46]. Canonical short variants such as inversions, insertions, translocations,
deletions, and duplications may introduce or interrupt elements in flanking regions; thus, they should
contribute to the formation of circRNAs. Although short repeats affect circRNA production, as found
in a previous reporter assay, it should be proven in clinical samples that some of the well-established
cancer-associated short variants correlate with cancers via circRNA [17]. Thus, a high-throughput
bioinformatics pipeline should be developed to analyze the large cancer sequencing datasets available
in the public repository. In a recent analysis of sequencing data from the dorsolateral prefrontal cortex,
Liu et al. combined the expression levels of circRNAs with genetic cis-acting SNPs and found that
partial circQTL SNPs might influence circRNA formation by altering the canonical splicing site or the
reverse complementary sequence match [47]. It would be interesting to conduct a similar approach in
cancer samples and to see if some of these circQTL SNPs are highly linked to genome-wide association
study signals in different cancer types.
Finally, circRNAs possess several characteristics that are well-suitable to serve as biomarkers in
cancers. Some circRNAs have tissue-specific expressions and correlate with clinical indicators [4,9,32].
They are protected from endonuclease degradation and are stable in formalin-fixed, paraffin-embedded
(FFPE) tissues [48]. Notably, recent reports have shown that circRNAs can be secreted in exosomes,
saliva, and urine [9,49,50]. Therefore, circRNAs could be further explored to be utilized as a surrogate
for cancer diagnostics.
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